Trials / Completed
CompletedNCT00044447
Evaluate the Role of Adding Amaryl to Non-Insulin Dependent Diabetes Mellitus Patients Unresponsive to Maximum Dose Metformin & Thiazolidinedione
A Double-Blind, Placebo-Controlled, Parallel Group Comparison Study to Evaluate the Role of the Addition of Amaryl to NIDDM Patients Not Responding to Maximum Dose Metformin and Thiazolidinedione Therapy
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 170 (actual)
- Sponsor
- Sanofi · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the efficacy and safety of Amaryl when added to Metformin and Thiazolidinedione (TZD) in non-insulin dependent diabetes mellitus (NIDDM) patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Glimepiride |
Timeline
- Start date
- 2001-05-01
- Completion
- 2002-09-01
- First posted
- 2002-08-30
- Last updated
- 2008-06-19
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00044447. Inclusion in this directory is not an endorsement.